Skip to main content
Premium Trial:

Request an Annual Quote

AssureRx Raises $11M in Series B Round

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – AssureRx Health has closed on an $11 million Series B round of private financing, the Cincinnati-based firm said today.

AssureRx is developing pharmacogenomic tests specifically for neuropsychiatric patients. Its GeneSightRx technology uses DNA from a cheek swab to measure and analyze genetic variants to determine how a patient will respond to psychotropic medications.

The firm said it will use the funds to expand its direct sales and marketing for GeneSightRx and for developing second-generation products.

The round of financing was led by Claremont Creek Ventures and Sequoia Capital. It also included existing investors Cincinnati Children's Hospital Medical Center, Mayo Clinic, and CincyTech, as well as new investor Allos Ventures. As part of the financing, John Steuart and Brad Webb of Claremont Creek Ventures have joined AssureRx's board of directors.

"Our goal is to build the leading medical informatics company providing pharmacogenetic and other treatment decision support products to help physicians individualize the treatment of patients with neuropsychiatric and other disorders," AssureRx President and CEO James Burns said in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.